Inhibikase Therapeutics holds annual shareholder meeting

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc.

IKT

0.00

  • Inhibikase Therapeutics held its annual shareholder meeting on June 26, 2026.
  • Shareholders authorized an amendment to the 2020 Equity Incentive Plan, adding 3,000,000 shares to the pool reserved for issuance.
  • Shareholders adopted an amendment to the certificate of incorporation to limit liability for certain officers; the amendment was filed and took effect June 26, 2026.
  • CohnReznick was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
  • Shareholders backed annual frequency for future advisory votes on executive compensation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-286747), on June 29, 2026, and is solely responsible for the information contained therein.